| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 223.89% | Truist Securities | → $4 | Reiterates | Buy → Buy |
| 08/07/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 06/06/2023 | 952.63% | EF Hutton | → $13 | Reiterates | → Buy |
| 05/26/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/24/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/16/2023 | 466.8% | Oppenheimer | $8 → $7 | Maintains | Outperform |
| 02/28/2023 | 547.77% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 02/08/2023 | -59.51% | Jefferies | → $0.5 | Downgrades | Hold → Underperform |
| 01/05/2023 | 952.63% | EF Hutton | → $13 | Initiates Coverage On | → Buy |
| 11/15/2022 | 547.77% | Oppenheimer | $12 → $8 | Maintains | Outperform |
| 08/23/2022 | 223.89% | Truist Securities | $14 → $4 | Maintains | Buy |
| 08/08/2022 | 223.89% | JMP Securities | $8 → $4 | Maintains | Market Outperform |
| 08/08/2022 | 871.66% | Oppenheimer | $14 → $12 | Maintains | Outperform |
| 08/05/2022 | 61.94% | Jefferies | → $2 | Downgrades | Buy → Hold |
| 02/25/2022 | 1033.6% | Oppenheimer | $17 → $14 | Maintains | Outperform |
| 02/25/2022 | 628.74% | SVB Leerink | $16 → $9 | Maintains | Outperform |
| 04/06/2021 | 1195.55% | SVB Leerink | $19 → $16 | Maintains | Outperform |
| 08/19/2020 | 1438.46% | SVB Leerink | $15 → $19 | Maintains | Outperform |
| 05/13/2020 | 1438.46% | Stifel | → $19 | Initiates Coverage On | → Buy |
| 05/07/2020 | 1114.57% | SVB Leerink | → $15 | Initiates Coverage On | → Outperform |
| 04/22/2020 | 2167.21% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 03/24/2020 | 1195.55% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/21/2020 | 952.63% | Cantor Fitzgerald | $10 → $13 | Reiterates | → Overweight |
| 01/16/2020 | 709.72% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
What is the target price for Compugen (CGEN)?
The latest price target for Compugen (NASDAQ: CGEN) was reported by Truist Securities on August 23, 2023. The analyst firm set a price target for $4.00 expecting CGEN to rise to within 12 months (a possible 223.89% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Compugen (CGEN)?
The latest analyst rating for Compugen (NASDAQ: CGEN) was provided by Truist Securities, and Compugen reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Compugen (CGEN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compugen was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
Is the Analyst Rating Compugen (CGEN) correct?
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $4.00. The current price Compugen (CGEN) is trading at is $1.24, which is within the analyst's predicted range.